Your browser doesn't support javascript.
loading
Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.
Davion, Jean-Baptiste; Cambron, M; Duhin, E; Chouraki, A; Lacour, A; Labauge, P; Carra, C; Ayrignac, X; Vermersch, P.
Affiliation
  • Davion JB; Univ. Lille, INSERM, CHU Lille, U995, LIRIC, Lille International Research Inflammation Center, 59000, Lille, France. jbdavion@hotmail.fr.
  • Cambron M; Univ. Lille, INSERM, CHU Lille, U995, LIRIC, Lille International Research Inflammation Center, 59000, Lille, France.
  • Duhin E; Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
  • Chouraki A; Univ. Lille, INSERM, CHU Lille, U995, LIRIC, Lille International Research Inflammation Center, 59000, Lille, France.
  • Lacour A; Univ. Lille, INSERM, CHU Lille, U995, LIRIC, Lille International Research Inflammation Center, 59000, Lille, France.
  • Labauge P; Univ. Lille, INSERM, CHU Lille, U995, LIRIC, Lille International Research Inflammation Center, 59000, Lille, France.
  • Carra C; Department of Neurology, University of Montpellier, Montpellier, France.
  • Ayrignac X; Department of Neurology, University of Montpellier, Montpellier, France.
  • Vermersch P; Department of Neurology, University of Montpellier, Montpellier, France.
J Neurol ; 263(7): 1361-3, 2016 Jul.
Article in En | MEDLINE | ID: mdl-27159986
ABSTRACT
We report two cases of primary progressive multiple sclerosis (PPMS) included in the INFORMS cohort, experiencing a relapse related to a single MRI gadolinium-enhancing lesion 3 months after fingolimod withdrawal. These two patients share similarities with relapsing-remitting multiple sclerosis cases described in the same situation, suggesting that the initiating process of the active demyelinating plaques is also present in PPMS, even without relapses, but may be triggered as fingolimod is withdrawn. Although the results of the INFORMS study suggest that fingolimod may not slow down the progression, some PPMS patients might still benefit from a disease-modifying treatment.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Substance Withdrawal Syndrome / Multiple Sclerosis, Chronic Progressive / Fingolimod Hydrochloride / Immunosuppressive Agents Limits: Humans / Male / Middle aged Language: En Journal: J Neurol Year: 2016 Document type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Substance Withdrawal Syndrome / Multiple Sclerosis, Chronic Progressive / Fingolimod Hydrochloride / Immunosuppressive Agents Limits: Humans / Male / Middle aged Language: En Journal: J Neurol Year: 2016 Document type: Article Affiliation country: France